Vanda Pharmaceuticals
VNDA
178 hedge funds and large institutions have $544M invested in Vanda Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 69 increasing their positions, 53 reducing their positions, and 22 closing their positions.
282% more call options, than puts
Call options by funds: $882K | Put options by funds: $231K
30% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 53
23% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 22
3% more funds holding
Funds holding: 173 → 178 (+5)
1.48% less ownership
Funds ownership: 98.99% → 97.51% (-1.5%)
11% less capital invested
Capital invested by funds: $611M → $544M (-$66.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$6.42M |
| 2 |
KAM
Krensavage Asset Management
New York
|
+$3.3M |
| 3 |
Allspring Global Investments
Charlotte,
North Carolina
|
+$2M |
| 4 |
Prudential Financial
Newark,
New Jersey
|
+$1.67M |
| 5 |
Bank of New York Mellon
New York
|
+$1.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$11M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$9.89M |
| 3 |
Renaissance Technologies
New York
|
-$3.6M |
| 4 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$3.43M |
| 5 |
Walleye Capital
New York
|
-$2.12M |
VNDA Hedge Fund Activity: Q3 2022 in Review
178 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q3 2022, worth a combined $544M — down 11% from $611M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new VNDA positions and 22 closed out — a net gain of 5 holders — while 69 added to existing stakes and 53 trimmed.
The largest buyer was Acadian Asset Management, adding an estimated $6.42M. The largest seller was Millennium Management, cutting an estimated $11M.
- 178 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q3 2022, up from 173 in Q2 2022.
- Funds reported $544M of Vanda Pharmaceuticals stock for Q3 2022, down 11% quarter-over-quarter.
- 27 funds opened new Vanda Pharmaceuticals positions in Q3 2022 and 22 closed out, a net change of +5 holders.
- The largest Vanda Pharmaceuticals buyer in Q3 2022 was Acadian Asset Management, an estimated $6.42M added.
- The largest Vanda Pharmaceuticals seller in Q3 2022 was Millennium Management, an estimated $11M sold.
Based on aggregated 13F filings for Q3 2022.